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Background: Heparin is a high risk medicine that may cause significant harm if not used properly. It is ranked among 
the top 5 “high alert” medications by the Institute of Safe Medication Practices because of its low therapeutic index 
and potential for serious adverse outcomes. Adherence to guidelines and protocols, as well as careful monitoring of 
heparin use, is important in maximizing benefits of its use and minimizing on harm. 
Objective: The aim of this study was to examine the processes and outcomes of heparin use in adult in- patients at the 
Rift Valley General Hospital through the conduct of a clinical audit. 
Methodology: A structured clinical audit tool was developed through consolidation of information from various 
sources. The structures supporting heparin use were physically assessed, including the availability of policies, 
guidelines or protocols, protamine and laboratory reagents. The processes and outcomes of its use were audited 
through the prospective observation of heparin dosing, administration and monitoring among eligible adult in-
patients.  
Results: Clinical audit revealed there were no policies, protocols or guidelines to guide heparin use at Rift Valley 
General Hospital. Delayed or lack of heparin monitoring were observed. Heparin termination was done well by 
introduction of warfarin at least three days before stopping heparin in majority of the patients. The overall clinical 
audit score at Rift Valley General Hospital was 60.6% which showed minimal compliance to the performance 
threshold/standard of heparin use. 
Conclusions: Clinical audit for heparin use in RVGH concluded inadequate compliance to the set standards. There is 
need to avail guidelines, protocols or policies in the institution and conduct regular monitoring to ensure use of 
heparin is improved and maximum benefit is realized.  
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1. Introduction 
Heparin is the most common parenteral anti-
thrombotic drug most widely used for the prevention 
and initial treatment of venous thromboembolism, for 
hemodialysis and cardiopulmonary bypass procedures 
and, with aspirin, for the management of acute coronary 
syndromes (European Medicines Agency, 2011, 
Scientific and Standardization Committee 
Communication, 2001). Heparin is on the World Health 
Organization's (WHO) List of Essential Medicines, a list 
of the most important medications needed in a basic 
health system. Heparin is also in the Kenya Essential 
Medicines List (KEML). As such, heparin should be 
available for use in patients from the National Referral 
Hospital right down to the Sub- District level of care. 
 Heparin is a high risk medicine that may cause 
significant harm if not used properly. Heparin therapy is 
associated with safety problems and the potential for 
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medication errors which may have serious/ significant 
consequences. Heparin has a low therapeutic index with 
potential to cause bleeding or clotting. Its use should be 
monitored to prevent possible errors and maximize 
benefits of use (ISMP Medication Safety alert, 2011). 
Heparin induced thrombocytopenia (HIT) is a 
prothrombotic complication mediated by auto 
antibodies against heparin-platelet complexes with a 
prevalence of between 10% -30% and fatal outcomes in 
5%–10% of cases (Douglas et al, 2013). HIT occurs less 
commonly with low molecular weight heparin (LMWH) 
than with unfractionated heparin (UFH) (Hirsh et al, 
2001). A report on the Royal Hospital for Women 
reported the incidence of HIT was 1-3% and 0-0.8% for 
UFH and LMWH respectively (Quality and Patient Safety 
Committee, 2015).  
While there are no documented reports of incidence 
and prevalence of heparin induced adverse outcomes in 
Kenya, the Seventh American College of Clinical 
Pharmacy (ACCP) Conference on Antithrombotic and 
Thrombolytic Therapy, indicated that the risk of 
hemorrhagic complication associated with IV (UFH) 
increases with increasing heparin dosages and age (> 
70 years) (Baglin et al, 2006). Monitoring of the 
anticoagulant effect of heparins is recommended, 
especially in the management of acute venous 
thromboembolism (VTE). This allows maximum 
antithrombotic effect with minimal risk of bleeding 
through over-anticoagulation.  However, accurate 
laboratory monitoring is often difficult (Baglin et al, 
2006). The activated Partial Thromboplastin Time 
(aPTT) is used to monitor therapeutic doses of UFH in 
venous thromboembolism.  A target ratio versus mid-
point of normal range of 1.5 to 2.5 is typically employed. 
This is principally based on evidence that delay in the 
achievement of adequate anticoagulation is associated 
with an increased rate of thrombosis recurrence or 
progression (Scientific and Standardization Committee 
Communication, 2001).  
Considering that heparin has a low therapeutic index 
and has potential to cause significant harm including 
death, it is important that its use is monitored closely to 
ensure that patients get maximum benefits. Harmful 
events with heparin have been associated with lack of 
use of policies, guidelines and proper monitoring 
(Payne et al, 2015). Finding out if guidelines and 
protocols on heparin use are being used by way of 
conducting a clinical audit is one way to ensure that 
patients are protected from avoidable harm. This study 
set out to develop an evidence-based Clinical Audit Tool 
for the evaluation of heparin use, and to apply this tool 
to examine the processes and outcomes of heparin use 
in adult in-patients at the Rift Valley General Hospital, 
Nakuru through the conduct a clinical audit. 
2. Methods 
2.1 Study site  
The study was carried out at Rift Valley general hospital 
(RVGH), the largest public teaching and referral hospital 
in Nakuru County, Kenya. It is currently the fourth 
largest government referral hospital in Kenya serving 
most of the South and Central Rift Valley and 
neighboring counties.  
2.2 Clinical Audit 
2.2.1 Development of the Clinical Audit Tool 
A clinical audit tool was developed to address three 
aspects of heparin use i.e. the structures, processes and 
outcomes which characterize heparin use.  The 
optimum standards of heparin use, audit criteria and 
targets/ levels of performance were set theoretically 
from Kenya’s Clinical Guidelines for Management and 
Referral of Common Conditions at Levels 4 – 6 : 
Hospitals  (Kenya’s Clinical Guidelines, 2009) and the 
Antithrombotic Therapy for Venous Thromboembolic 
Disease. American College of Chest Physicians Evidence-
Based Clinical Practice Guidelines (8th Edition) (Kearon 
et al, 2008) which formed the basis of comparison with 
actual practice at RVGH. The structure and format of the 
clinical audit tool was adapted from the Leicestershire 
partnership NHS Trust (August 2008) 
(www.leicspart.nhs.uk). 
2.2.2 Implementation of the audit 
The implementation of the audit involved collection of 
data on the structures, processes and outcomes of 
heparin use, using the clinical audit tool developed. The 
structures supporting heparin use were physically 
assessed, including the availability of policies, 
guidelines or protocols, protamine (heparin antidote) 
and laboratory reagents. The processes and outcomes of 
heparin use were audited through the prospective 
observation of heparin dosing, administration and 
monitoring among eligible adult in-patients. Patients 
were interviewed for information on satisfaction of 
care. The audit was structured into four audit criteria, 
where each audit criteria addressed a specific aspect of 
heparin use (Table 1). The questions under each 
criterion aimed to describe in a measurable way what 
care should be delivered, and included policies, 
procedures and requirements.  
 2.2.3 Analysis of audit data 
Data analysis involved comparison of clinical audit data 
that was retrieved with the pre-set audit criteria and 
targets/ levels of performance. Simple descriptive 
statistics were used to analyze the data i.e. averages and 
percentages. Each audit criterion (Table 1) had several 
questions with each question answered Yes having a 
score of 10 and each No having a score of 0. Averages 
were calculated to obtain overall criterion score. These 
scores were then compared with the pre-set audit 
criteria and targets/ levels of performance to inform 
how use of heparin at RVGH compared with the set 
standards. After the audit, a Quality Improvement Plan 
was developed to address the gaps that were identified. 
2.3 Ethical Considerations 
Ethical approval was sought and obtained from 
KNH/UON Ethics and Research Committee 
(P644/10/2015). Institutional approval was also 
sought and obtained from RVGH (RII/VOL.I/08). 
Special patient identifiers were used by the investigator 
instead of names to ensure confidentiality. Informed 
consent was sought for patient descriptive information 
interviews (satisfaction on patient care). 
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Table 1: Standards for Heparin Use in Adult In-Patients 
Audit Criteria Standard/Threshold Description 
Structural features 
There are adequate supporting structural 
features in the organization to enable safe 
use of heparin. 
100% 
Structural features should be 
adequate to allow safe use of heparin 
Competent staff 
There are sufficient competent persons to 
provide appropriate heparin use service. 
100% 
All staff handling heparin should be 
competent to avoid errors  
Safe use of heparin 
Proper precautions are taken to ensure that 
patients requiring heparin are prescribed, 
administered and monitored appropriately. 
100% 
No inefficiencies are allowed during 
prescribing, administration and 
monitoring of heparin 
Patient satisfaction on quality of care 
Patients are happy with the care that they 
receive in the institution 
80% 
Some patients may not be able to 
respond and caregivers may not be 
present 
 
3. Results  
The clinical audit tool (appended) was put together 
through a consolidation of information from various 
sources including the Clinical Guidelines for 
Management and Referral of Common Conditions at 
Levels 4 – 6 : Hospitals  (Kenya’s Clinical Guidelines, 
2009) and the Antithrombotic Therapy for Venous 
Thromboembolic Disease. American College of Chest 
Physicians Evidence-Based Clinical Practice Guidelines 
(8th Edition) (Kearon et al, 2008), the Leicestershire 
partnership NHS Trust (www.leicspart.nhs.uk), a 
clinical audit on Chronic Obstructive Pulmonary Disease 
(COPD) by (Moore et al, 2013),  the Clinical Guidelines 
from the National Institute for Health and Clinical 
Excellence (NHS), specifically the (NICE Clinical 
Guideline 92, 2010) and the clinical audit forms by 
Healthcare Quality Quest Limited in the UK 
(www.hqq.co.uk).   
The general structure consisted of six sections, as 
follows:  
Section 1: this section was designed to collect 
information about the place/facility where audit 
takes place, audit period/date and wards/units 
involved.  
Section 2: this section presents optimum standards 
for heparin use in adult in-patients, against which 
findings of clinical audit are to be compared.  
Section 3: this is the data collection section of audit 
tool. There are series of targeted questions whose 
responses allow scoring and audit of each of four 
main criteria that were identified for this audit.  
Section 4: this section presents instructions on how 
to score criteria, and provides a table to guide in 
calculation of scores per each criteria.  
Section 5: this section is an overall summary of 
assessment of each criterion as per the relevant set 
standards of performance. 
Section 6: this section presents a template for the 
Quality Improvement Action Plan. This informs the 
action points to improve quality of delivery of 
services. It also informs basis for a re-audit for 
purposes of completion of audit cycle. 
A summary of the standard/ performance thresholds 
that were set for the clinical audit of heparin is shown in 
(Table 1). These threshold values act as checkpoints 
and help in monitoring the performance of a particular 
criterion by providing a benchmark value. It has been 
recommended that all criteria for standards of care are 
set at 100%. However, in cases where deviations from 
complete compliance may be tolerated, standards for 
such criteria can be set at 80% (Moore et al, 2013). 
The key for interpretation of level of compliance from 
scores and pre-set performance thresholds was set as 
illustrated in Table 2. 
Clinical Audit of Heparin Use at RVGH 
Criterion 1 (performance threshold/standard set at 
100%) had an observed score of 83.3% which according 
to the NICE guidance for interpretation of audit showed 
partial compliance. The deficiencies that were identified 
by the audit were absence of standard guidelines/ 
protocols or policies on heparin use and absence of anti-
dote protamine sulphate. 
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Criterions 2 and 3 (performance thresholds/standards 
set at 100%) showed minimal compliance at 55.5% and 
37.5% respectively. The audit identified that no staff 
had gone through post-qualification training on heparin 
use, LMWH-patients weights were not taken to 
determine doses, weight measurements were not 
repeated in course of treatment and renal function tests 
were not considered. Furthermore, UFH-baseline 
aPTT/INR was not routinely taken within 6 hours of 
initiation of therapy, and full blood counts (FBC) were 
not taken at least once every week.  
Criterion 4 (performance threshold/standard set at 
80%) had an observed score of 50% which meant that 
this criterion had minimal compliance to the 
performance threshold/standard. The audit identified 
that health care workers do not satisfactorily respond 
promptly to patients’ calls. 
The overall clinical audit at RVGH was found to be 
60.6% which showed minimal compliance to the 
performance threshold/standard of heparin use. The 
summary of scores per criterion is shown in Table 3 
below. 
 
Table 2: Key for interpretation of the Level of Compliance with the set Performance Threshold (Moore et al, 2013) 
Performance threshold/ Standard at 100% 
Full compliance   Partial compliance Minimal compliance 
90%  𝑥 100% 70% 𝑥<89% 𝑥< 69% 
Performance threshold/ Standard at 80% 
Full compliance   Partial compliance Minimal compliance 
72%  𝑥 80% 56% 𝑥<71% 𝑥< 55% 
 
Table 3:  Criterion Scoring Sheet 
 
Criterion 
 
 
Actual Criterion 
Score (AC) 
Maximum Criterion Score (MC)= 
Total Number of Questions x 
Maximum Score (10) 
Criterion Score as a 
percentage= (AC/MC x 100/1) 
1 100 120 (100/120)*100 = 83.3% 
2 50 90 (50/90)*100 = 55.5% 
3 30 80 (30/80)*100 = 37.5% 
4 20 40 (20/40)*100 = 50% 
Overall audit score = (∑ AC/ ∑MC)* 100 = (200/330) * 100 = 60.6% 
 
4.0 Discussion 
A tool for conducting regular clinical audits on heparin 
use was formulated and subsequently used to conduct 
the clinical audit of heparin use at RVGH. 
Clinical audit of Criterion 1 revealed that there were no 
standards or protocols of heparin use in the institution, 
and no protamine sulphate was available. It was found 
out that the tests used for heparin use monitoring 
(aPTT, INR and FBC) were introduced at RVGH in March 
2016. However, the uptake is low due to cost 
constraints and some prescribers prefer sending 
patients outside RVGH for the same tests to be done by 
private practitioners in Nakuru town. In case of any 
emergency such as hemorrhage, hypersensitivity 
reaction or HIT, the possibility of patient dying is high 
without protamine in the facility. 
Criterion 2 revealed that none of the staff had ever been 
taken through post- qualification training on 
appropriate heparin use. For improvement in the 
proper heparin use to be achieved, staff need to be 
orientated on guidelines, protocols and policies that 
guide heparin use. Similar findings were reported by 
(Vikrant et al, 2007). This study was carried out in the 
community hospitals in the United States and it found 
that guidelines, protocols, or policies on use of 
anticoagulants are often lacking. 
 Criterion 3 revealed some processes were closer to the 
required standard and need to be maintained, such as 
the introduction of warfarin at least three days before 
the cessation of heparin. However, the audit also 
revealed inadequate monitoring of heparin. The 
infrequent monitoring of heparin therapy has also been 
reported elsewhere by (Baglin et al, 2006) and (Quigley 
et al, 1988). These two are guidelines on the use and 
monitoring of heparin by the British Society for 
Haematology (British Committee for Standards in 
Haematology) and they acknowledge that monitoring of 
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heparin treatment is not frequently practiced and it is 
often difficult to achieve. 
Criterion 4 revealed the patients are generally satisfied 
with the quality of care at the RVGH. The overall 
criterion score was 50%. This is probably because the 
staff is friendly. The implication of this finding may be 
that the patients are likely to recommend other patients 
to go to RVGH. A similar finding was found by (Aiken et 
al, 2012) in Europe and the United States who 
established that patients were more likely to 
recommend other patients to a particular hospital with 
good hospital environment. However we feel an 
improvement should be made on the responsiveness to 
patients’ calls. 
A Quality Improvement Plan was developed to address 
the gaps that were found after the audit. This plan 
recommended that standards/ protocols or policies 
addressing heparin use be put in place, and protamine 
sulphate should be availed in the hospital. It is also 
recommended that all staff involved in heparin use 
should be trained on its appropriate use, and that health 
care workers should respond to patient call without 
delays. 
It was also recommended that the management of the 
RVGH review and address any gaps that they may find 
in the Heparin audit tool depending on the institutional 
needs. It’s also hoped that the management of the RVGH 
will implement the recommendations of the Quality 
Improvement Action plan, and thereafter conduct a re-
audit to complete the clinical audit cycle.  
5.0 Conclusion  
Clinical audit for heparin use in RVGH concluded 
minimal compliance to the set standards. This means 
that there is need to put some strategies as described 
above in place to ensure use of heparin is improved and 
there is maximum benefit obtained. 
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CLINICAL AUDIT TOOL FOR HEPARIN USE FOR ADULT IN-PATIENTS 
SECTION 1: GENERAL INFORMATION 
Ward and health service: Facility: Audit date/Period: 
Ward/Unit: Patient/ HCW No.: 
Data Collector (Clinical Auditor):  
 
General Instructions: 
 Data will be collected prospectively or retrospectively from existing records as the case may be. 
 Use one clinical audit tool per patient or Health care worker audited. 
 Each facility needs to determine those audit questions that are applicable to their facility / health 
service circumstances for review. 
 Some questions and responses may not be applicable (e.g. at a ward/unit level) and can be 
adapted to suit individual requirements.  
             Scores: Yes = 10, No = 0, N/A = doesn’t count in final score. 
 
This clinical audit tool consists of six sections each with a specific function. All the sections should be filled in 
correctly and fully. 
This is the first version of the audit tool, and future versions will build upon the existing scope 
and questions, and incorporate staff feedback and suggestions for improvement.   
Feedback on this audit tool and the measurement plans is therefore encouraged, to ensure the 
tool meets the needs of Hospital and Health Services.  
 
SECTION 2: STANDARDS FOR HEPARIN USEIN ADULT IN- PATIENTS 
Performance threshold/standards are the minimum acceptable performance standards or the maximum 
allowable limits. The threshold values act as checkpoints and help in monitoring the performance of a 
particular criterion by providing a benchmark value. 
Audit Criteria Standard/Threshold Description 
Structural features 
There are adequate supporting structural 
features in the organization to enable safe 
use of heparin. 
100% 
Structural features should be 
adequate to allow safe use of heparin 
Competent staff 
There are sufficient competent persons to 
provide appropriate heparin use service. 
100% 
All staff handling heparin should be 
competent to avoid errors  
Safe use of heparin 
Proper precautions are taken to ensure that 
patients requiring heparin are prescribed, 
administered and monitored appropriately. 
100% 
No inefficiencies are allowed during 
prescribing, administration and 
monitoring of heparin 
Patient satisfaction on quality of care 
Patients are happy with the care that they 
receive in the institution 
80% 
Some patients may not be able to 
respond and caregivers may not be 
present 
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SECTION 3: AUDIT DATA COLLECTION TOOL 
This section contains the criteria used to perform the audit. There are four criteria each of which consists 
specific questions to assess heparin use in an institution.  
Instruction:  
 Use one clinical audit tool per patient or Health care worker audited. 
 Each facility needs to determine those audit questions that are applicable to their facility/ health service 
circumstances for review. 
 Some questions and responses may not be applicable (e.g. at a ward/unit level) and can be adapted to suit 
individual requirements.  
 
CRITERION 1: Structural features 
This section examines the adequacy of supporting structural features in the organization to enable safe use of 
heparin. 
Source of data and specific instruction: Data to be extracted from physical check in the pharmacy, laboratory, 
wards, Health Management information System (HMIS) and the human resource department (HRD). The 
auditor may seek the help of a staff in the relevant departments for guidance. 
NOTE: Only one form to be used for this section 
 QUESTION RESPONSE 
1.1 Are there protocols, policies and guidelines for heparin use? Yes ( )    No ( ) 
1.2 Are the following staff available in your facility per cadre? 
i. Consultants 
ii. Medical Officers 
iii. Pharmacists 
iv. Clinical Officers 
v. Nursing Officers 
vi. Pharmaceutical technologists 
vii. Laboratory technologists 
 
Yes ( )    No ( ) 
Yes ( )    No ( ) 
Yes ( )    No ( ) 
Yes ( )    No ( ) 
Yes ( )    No ( ) 
Yes ( )    No ( ) 
Yes ( )    No ( ) 
1.3 Are laboratory reagents available for performing relevant tests? 
FBC 
aPTT 
INR 
 
Yes ( )    No ( ) 
Yes ( )    No ( )  
Yes ( )    No ( ) 
1.4 
 
Is Protamine Sulphate available in the Pharmacy/service user 
areas? 
Yes ( )    No ( ) 
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CRITERION 2: Competent staff 
This section examines if there are sufficient competent persons to provide appropriate heparin use service. 
Source of data and specific instruction: Data to be obtained from interviewing the Health care workers. The 
staff to be interviewed are those that handle heparin at any point during prescribing, dispensing, 
administration or monitoring. 
NOTE: One form for each staff interviewed. 
 
 QUESTION RESPONSE 
2.1 What is your cadre? Physician/ Consultant( ) 
Medical officer ( ) 
Med. Officer intern ( ) 
RCO      ( ) 
CO Intern ( ) 
Nursing Officer  ( ) 
Pharmacist ( ) 
Other (specify)  ( ) 
2.2 How many years have been in service? <5 Years ( ) 
5-10 Years  ( ) 
>10 Years  ( ) 
2.3 Have you ever received post-qualification training on heparin use? Yes ( )    No ( ) 
2.4 If yes in Q 2.3, which specific area were you trained on? Prescribing ( ) 
Dispensing  ( ) 
Administration ( ) 
Monitoring  ( ) 
2.5 Do you have any protocols/ standards or guidelines in place for 
heparin use? 
Yes ( )    No ( ) 
2.6 If yes in Q 2.5, which specific resources do you use? _______________________________ 
_______________________________ 
_______________________________ 
_______________________________ 
2.7 Do you have antidote Protamine Sulphate available to you when 
using heparin? 
Yes ( )    No ( ) 
2.8 How do you monitor heparin therapy?  
aPTT 
INR 
FBC 
 
Yes ( )    No ( ) 
Yes ( )    No ( ) 
Yes ( )    No ( ) 
2.9 How often do you monitor FBC for HIT? 
Weekly 
After every two weeks 
Never 
 
Yes ( )    No ( ) 
Yes ( )    No ( ) 
Yes ( )    No ( ) 
 
Gichobi et al, Afr. J. Pharmacol. Ther. 2017. 6(1): 27-37 
 
A KeSoBAP Publication ©2017. All rights reserved. 
35 
CRITERION 3: Safe use of heparin 
Proper precautions are taken to ensure that patients requiring heparin are prescribed, administered and 
monitored appropriately.  
Source of data and specific instruction: Data to be obtained from observation of processes during heparin use. 
Further information to be obtained from the patient files. 
 QUESTION RESPONSE 
3.1 What type of heparin was prescribed? ( ) UFH      ( ) LMWH 
3.2 For LMWH, was patient weight taken before start of            
therapy? 
Yes ( )    No ( ) 
3.3 Was patient weight repeated in the course of treatment? Yes ( )    No ( )  N/A ( ) 
3.4 Was the patient’s weight used as the basis for calculating the 
treatment dose with LMWH? 
Yes ( )    No ( ) 
3.5 Was renal function considered during prescribing treatment 
dose with LMWH? 
Yes ( )    No ( )  N/A ( ) 
3.6 For UFH, were APTT/ INR done 6 hours after initiation of 
treatment? 
Yes ( )    No ( )  N/A ( ) 
3.7 Were APTT /INR repeated 3 days after initiation of therapy? Yes ( )    No ( )  N/A ( ) 
3.8 Was FBC checked at least once every week? Yes ( )    No ( )  N/A ( ) 
3.9 Was heparin use continued for at least 4 days after the 
initiation of warfarin? 
Yes ( )    No ( )  N/A ( ) 
 
CRITERION 4: Patient satisfaction on quality of care 
Majority of patients are satisfied with the quality of care that they receive in the institution. 
Source of data and specific instruction: Data to be obtained from interviewing the patients and patient files. 
Where the patient cannot be able to respond to questions and a caregiver is available then the question can 
be directed to the caregiver.   
NOTE: One form to be used for one patient                  
 QUESTION RESPONSE 
4.1 Are Health Care Workers (HCW) friendly to you? Yes ( )    No ( )   Not sure( ) 
4.2 Do Health Care Workers (HCW) answer to your call promptly? Yes ( )    No ( ) 
4.3 What do you feel about the overall quality of care? Satisfied ( ) 
Not satisfied ( ) 
Don’t know ( ) 
4.4 Were there any adverse effects following heparin use that is 
recorded? 
Yes ( )    No ( ) 
 
4.5 
 
If Yes in 4.4, were there investigations done to confirm if heparin was 
the cause? 
 
_______________________________ 
_______________________________ 
_______________________________ 
_______________________________ 
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SECTION 4: CRITERION SCORING SUMMARY SHEET 
Scoring instructions: Scores: Yes = 10, No = 0, N/A = doesn’t count in final score. A score of ten is assigned to 
every Yes answer and a score of zero to every No answer. In case the answer is not applicable, then there is 
no score assigned and that particular question will not apply when computing the final criterion score.  
The Actual Criterion Score is obtained by adding up all the Yes answers multiplied by 10 
 
Criterion 
 
 
Actual Criterion 
Score (AC) 
Maximum Criterion Score (MC) = 
Total Number of Questions x 
Maximum Score (10) 
Criterion Score as a 
percentage= (AC/MC x 100/1) 
1    
2    
3    
4    
Overall audit score = (∑ AC/ ∑MC)* 100  
 
Interpretation of audit results as per NICE guidance: 
Performance threshold/ Standard at 100% 
Full compliance Partial compliance Minimal compliance 
90%  𝑥 100% 70% 𝑥<89% 𝑥< 69% 
Performance threshold/ Standard at 80% 
Full compliance Partial compliance Minimal compliance 
72%  𝑥 80% 56% 𝑥<71% 𝑥< 55% 
 
   SECTION 5: CRITERION ASSESSMENT PER SET STANDARDS 
 CRITERION PERFORMANCE 
THRESHOLD (%) 
OBSERVED 
(%) 
COMMENT 
1 
 
 
Structural features  
There are adequate supporting structural 
features in the organization to enable safe 
use of heparin. 
See section 3, Criterion 1 
100% 
 
  
2 
 
Competent staff  
There are sufficient competent persons to 
provide appropriate heparin use service. 
See section 3, Criterion 2 
100% 
 
  
3 
 
 
Safe use of heparin  
Proper precautions are taken to ensure 
that patients requiring heparin are 
prescribed, administered and monitored 
appropriately. 
See section 3, Criterion 3 
100% 
 
  
4 Patient satisfaction on quality of care  
Patients are satisfied with the quality of 
care that they receive in the institution 
See section 3, Criterion 4 
80% 
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SECTION 6: QUALITY IMPROVEMENT ACTION PLAN 
Criterion 
Area of Non 
Compliance 
Corrective 
Action to be 
Taken 
Responsible 
Person 
Timeframe 
Review of 
Implementation 
of Action (Audit) 
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